1.A 35-year-old hemophiliac with pseudotumor of the thigh.
Panganiban Michelle O. ; Ramirez Mae N. ; Zamora Rosally P. ; Escasa Ivy Mae S ; Mejia Agnes D. ; Vergel De Dios Ariel M.
Acta Medica Philippina 2010;44(3):72-77
Human
;
Male
;
Adult
;
Young Adult
;
Hemophilia A
;
Neoplasms
;
Thigh
;
Lower Extremity
2.Osteosarcoma in the preadolescent Filipino patient
Wang Edward H.M. ; Valenzuela Julius N. ; Decenteceo Ana Cristina D. ; Dy Amy Goleta ; Alcasabas Ana Patricia A. ; Vergel De Dios Ariel M. ; Serrano Ma. Victoria T. ; Dimayuga Cesar L. ; Quintos Albert Jerome C.
Acta Medica Philippina 2011;45(2):24-29
Objective. Classic high-grade osteosarcoma is uncommon in preadolescents (less than or equal to 10 years of age). The possibilities of
clinicopathologic differences from the typical adolescent osteosarcoma patient have been raised. We sought to compare the presentation, treatment and survival of this subgroup of patients with published rates in order to determine if there is a need to use a treatment regimen different from that for regular adolescent osteosarcoma patients.
Methods. Records of the University of the Philippines-Musculoskeletal Tumor Unit (UP-MuST) over a 15-year period (1993-2008) were reviewed and data collected on patients 10 years and younger with biopsy-proven classic high-grade intramedullary osteosarcoma who underwent complete treatment by the Unit. Demographics and survival rates were then compared with published rates for preadolescent and regular adolescent osteosarcoma cases.
Results. There were fourteen patients; (6M:8F; age: 4-10 years). The most common presentation was a painful mass in the distal femur (8); the tumors most commonly had osteoblastic histology (12). Treatment consisted of neoadjuvant chemotherapy, wide surgical excision through ablation (9) or limb-saving surgery (5), and postoperative chemotherapy. There was a good histologic response (over 90% tumor necrosis) in four patients. Seven patients are ANED (alive no evidence of disease) 25 to 186 months after diagnosis. Five-year survival estimate is 52%, compared to a dismal 5 to 10% 15 years ago.
Conclusion. Clinicopathologic presentation, clinical course, and overall survival in this subgroup of patients are comparable with published results for both preadolescent and adolescent osteosarcoma patients. There is no need to alter the present treatment regimen for this group of young patients.
Human
;
Male
;
Female
;
Child
;
Child Preschool
;
OSTEOSARCOMA
;
THERAPEUTICS
;
THERAPY
;
NEOPLASMS
;
NEOPLASMS BY HISTOLOGIC TYPE
;
NEOPLASMS, CONNECTIVE AND SOFT TISSUE
;
NEOPLASMS, CONNECTIVE TISSUE
;
NEOPLASMS, BONE TISSUE
;
3.Primary sinonasal ameloblastoma in a Filipino female.
Mark Angelo C. Ang ; Ariel M. Vergel De Dios ; Jose M. Carnate, Jr.
Philippine Journal of Otolaryngology Head and Neck Surgery 2011;26(2):39-41
Primary sinonasal ameloblastoma is an extremely rare odontogenic epithelial tumor histomorphologically identical to its gnathic counterparts but with distinct epidemiologic and clinicopathologic characteristics. We present a case of a 46-year-old female with a one year history of recurrent epistaxis, nasal obstruction and frontonasal headache. Clinical examination, CT scan and subsequent surgical excsion revealed an intranasal mass attached to the lateral nasal cavity with histomorphologic features of ameloblastoma and was signed out as extragnathic soft tissue ameloblastoma of the sinonasal area. Extraosseous extragnathic primary sinonasal ameloblastoma are rare but do occur and should be distinguished from infrasellar craniopharyngiomas.
Human ; Female ; Middle Aged ; AMELOBLASTOMA ; ODONTOGENIC TUMORS ; CALCIFYING EPITHELIAL ODONTOGENIC TUMOR ; NEOPLASMS BY HISTOLOGIC TYPE ; NEOPLASMS ; EPISTAXIS ; RECURRENCE ; DIAGNOSTIC IMAGING ; MEDICAL IMAGING ; DIAGNOSTIC TECHNIQUES AND PROCEDURES ; TOMOGRAPHY SCANNERS, X-RAY COMPUTED
4.Non-parametric clinical laboratory reference interval estimation in volunteer blood donors: An example for prothrombin time and partial thromboplastin time
Mark Angelo Ang ; Nelson Geraldino ; Ariel Vergel de Dios ; Marimin Abad-Lapuebla
Philippine Journal of Pathology 2022;7(2):23-27
Introduction:
To date, there are no reference intervals for prothrombin time (PT) and activated partial thromboplastin time (APTT) based on “normal” Filipino adults. The common practice in most laboratories is to adopt manufacturer provided values or foreign literature even if the importance of establishing or at least verifying laboratory reference intervals has been stressed by Clinical Laboratory Standards Institute (CLSI).
Objectives:
Here we aim to describe our experience in using a simple non-parametric method to generate reference intervals for PT and APTT, from healthy Filipino volunteer blood donors.
Methodology:
We used a de novo, a priori non-parametric estimation method following the CLSI guidelines on establishing reference intervals.
Results:
The non-parametric lower reference limit for PT is 12.55 seconds, with 90% confidence interval of 12.3 to 12.75 seconds. While the non-parametric upper reference limit for PT is 16.15 seconds, with 90% confidence interval of 15.55 to 16.55 seconds. The non-parametric lower reference limit for activated partial thromboplastin time is 26.12 seconds, with 90% confidence interval of 22.95 to 27.1 seconds, and the non-parametric upper reference limit for activated partial thromboplastin time is 37.44 seconds, with 90% confidence interval of 36.75 to 38.65 seconds. The PT and APTT reference intervals were different from foreign sources and manufacturer provided values in terms of interval width and values of the reference limits by 2 to 4 seconds.
Conclusion and Recommendations
Estimation of coagulation reference intervals from volunteer health blood donors is doable, simple, and practical. Collaborative multi-center efforts may be done to expand the pool of reference individuals that are included and increase the representativeness of the reference intervals generated. This simple method can also be used to generate reference intervals for other clinical laboratory assays and may also be extended to at least verify reference intervals in special populations like pregnant women, the elderly, and the pediatric population.
Prothrombin Time
;
Partial Thromboplastin Time